Alnylam Pharmace. buy Shooter
Summary
This prediction ended on 07.02.24 with a price of €161.00. The prediction for Alnylam Pharmace. disappointed with a performance of -24.78%. Shooter has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Shooter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | 2.115% | 2.115% | 30.609% |
iShares Core DAX® | 1.395% | -0.696% | 15.472% |
iShares Nasdaq 100 | 2.287% | 7.501% | 34.748% |
iShares Nikkei 225® | 1.617% | 2.769% | 11.442% |
iShares S&P 500 | 0.659% | 4.280% | 26.778% |
Comments by Shooter for this prediction
In the thread Trading Alnylam Pharmace.